| Prescription ID | TCMF29 |
| Pinyin Name | Fu Fang Zhen Zhu Kou Chuang Ke Li |
| Chinese Name | 夿–¹çç å£ç–®é¢—ç²’ |
| English Name | Fu Fang Zhen Zhu Kou Chuang Granules |
| Function Description | 心脾湿çƒè¯å£ç–®, ç—‡è§å£ç–®, 周围红肿, ä¸é—´å‡¹é™·, 表é¢é»„白, ç¼çƒç–¼ç—›, å£å¹²å£è‡, 舌红 |
| Indications | Heat pattern, Aphtha |
| Disease ICD-11 Category |
SE72 [Heat pattern (TM1), çƒè¯ (TM1)
]; DA01.10 [Oral aphthae or aphtha-like ulceration, å£è…”é˜¿å¼—ä»–æºƒç–¡æˆ–é˜¿å¼—ä»–æ ·æºƒç–¡ ]; |
| Human Tissues Associated with Indication | Skin, Lung |
| Reference | Chinese pharmacopoeia (2015) |
| Reference Book/link | ISBN 978-7-5067-7337-9 |
| Component ID | Latin Name | Chinese Name | Component Quantity | Barcode |
|---|---|---|---|---|
| TCMH211 | Atractylodes lancea | è‹æœ¯ | TCMH211 | ITSAN4439-14 |
| TCMH628 | Glycyrrhiza uralensis | ç”˜è‰ | TCMH628 | ITSAM892-14 |
| TCMH2605 | Margarita | çç | TCMH2605 | |
| TCMH2175 | Galla chinensis | 五å€å | TCMH2175 |
| Target ID | Gene Symbol | Target Name | Target Class | Uniprot ID |
|---|---|---|---|---|
| TCMT100 | TTR | Transthyretin | Unclassified | P02766 |
| TCMT101 | PTPN1 | Protein-tyrosine phosphatase 1B | Hydrolase | P18031 |
| TCMT112 | ADORA3 | Adenosine A3 receptor | GPCR | P0DMS8 |
| TCMT127 | PARP1 | Poly [ADP-ribose] polymerase-1 | Transferase | P09874 |
| TCMT128 | TNKS2 | Tankyrase-2 | Transferase | Q9H2K2 |
| TCMT129 | TNKS | Tankyrase-1 | Transferase | O95271 |
| TCMT131 | ACHE | Acetylcholinesterase | Hydrolase | P22303 |
| TCMT133 | CA1 | Carbonic anhydrase I | Lyase | P00915 |
| TCMT134 | CA2 | Carbonic anhydrase II | Lyase | P00918 |
| TCMT135 | CA14 | Carbonic anhydrase XIV | Lyase | Q9ULX7 |
| TCMT136 | CA12 | Carbonic anhydrase XII | Lyase | O43570 |
| TCMT137 | CA9 | Carbonic anhydrase IX | Lyase | Q16790 |
| TCMT138 | CA7 | Carbonic anhydrase VII | Lyase | P43166 |
| TCMT142 | CA4 | Carbonic anhydrase IV | Lyase | P22748 |
| TCMT156 | CYP19A1 | Cytochrome P450 19A1 | Oxidoreductase | P11511 |
| TCMT159 | TYR | Tyrosinase | Oxidoreductase | P14679 |
| TCMT162 | UGT1A1 | UDP-glucuronosyltransferase 1-1 | Transferase | P22309 |
| TCMT17 | POLB | DNA polymerase beta | Transferase | P06746 |
| TCMT174 | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | Oxidoreductase | P28845 |
| TCMT190 | PTPN2 | T-cell protein-tyrosine phosphatase | Hydrolase | P17706 |
| TCMT209 | HSD11B2 | 11-beta-hydroxysteroid dehydrogenase 2 | Oxidoreductase | P80365 |
| TCMT215 | CYP1A1 | Cytochrome P450 1A1 | Oxidoreductase | P04798 |
| TCMT219 | CYP1A2 | Cytochrome P450 1A2 | Oxidoreductase | P05177 |
| TCMT223 | AKR1B1 | Aldose reductase | Oxidoreductase | P15121 |
| TCMT23 | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | Hydrolase | P05186 |
| TCMT231 | GBA2 | Beta-glucosidase | Hydrolase | Q9HCG7 |
| TCMT236 | ESR2 | Estrogen receptor beta | Nuclear receptor | Q92731 |
| TCMT249 | CDK6 | Cyclin-dependent kinase 6 | Kinase | Q00534 |
| TCMT257 | CYP1B1 | Cytochrome P450 1B1 | Oxidoreductase | Q16678 |
| TCMT260 | FLT3 | Tyrosine-protein kinase receptor FLT3 | Kinase | P36888 |
| TCMT261 | DAPK1 | Death-associated protein kinase 1 | Kinase | P53355 |
| TCMT280 | AKR1B10 | Aldo-keto reductase family 1 member B10 | Oxidoreductase | O60218 |
| TCMT296 | ADORA1 | Adenosine A1 receptor | GPCR | P30542 |
| TCMT297 | FABP4 | Fatty acid binding protein adipocyte | Unclassified | P15090 |
| TCMT298 | FABP3 | Fatty acid binding protein muscle | Hydrolase | P05413 |
| TCMT337 | XPO1 | Exportin-1 | Unclassified | O14980 |
| TCMT344 | AOX1 | Aldehyde oxidase | Oxidoreductase | Q06278 |
| TCMT46 | F3 | Coagulation factor III | Unclassified | P13726 |
| TCMT47 | BCL2 | Apoptosis regulator Bcl-2 | Ion channel | P10415 |
| TCMT506 | PTK2B | Protein tyrosine kinase 2 beta | Kinase | Q14289 |
| TCMT563 | CDC25B | Dual specificity phosphatase Cdc25B | Hydrolase | P30305 |
| TCMT591 | ESRRA | Estrogen-related receptor alpha | Nuclear receptor | P11474 |
| TCMT592 | XDH | Xanthine dehydrogenase | Oxidoreductase | P47989 |
| TCMT597 | SLC28A3 | Solute carrier family 28 member 3 | Transporter | Q9HAS3 |
| TCMT63 | PPARA | Peroxisome proliferator-activated receptor alpha | Nuclear receptor | Q07869 |
| TCMT636 | POLA1 | DNA polymerase alpha subunit | Transferase | P09884 |
| TCMT65 | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | Oxidoreductase | P14061 |
| TCMT66 | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | Oxidoreductase | P37059 |
| TCMT709 | SLC28A2 | Sodium/nucleoside cotransporter 2 | Transporter | O43868 |
| TCMT710 | SLC28A1 | Sodium/nucleoside cotransporter 1 | Transporter | O00337 |
| TCMT734 | MMP12 | Matrix metalloproteinase 12 | Hydrolase | P39900 |
| TCMT752 | CSNK2A1 | Casein kinase II alpha | Kinase | P68400 |
| TCMT808 | FABP5 | Fatty acid binding protein epidermal | Unclassified | Q01469 |
| TCMT809 | FABP2 | Fatty acid binding protein intestinal | Unclassified | P12104 |
| TCMT810 | TLR2 | Toll-like receptor 2 | Unclassified | O60603 |
| TCMT82 | ESR1 | Estrogen receptor alpha | Nuclear receptor | P03372 |
| TCMT822 | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Transferase | Q11130 |
| TCMT83 | CD38 | Lymphocyte differentiation antigen CD38 | Unclassified | P28907 |
| TCMT907 | FDPS | Farnesyl diphosphate synthase | Lyase | P14324 |
| TCMT910 | ESRRB | Estrogen-related receptor beta | Nuclear receptor | O95718 |
| Target ID | Target Name |
|---|---|
| TCMT1170 | Enterobacter cloacae |
| TCMT1175 | Human immunodeficiency virus |
| TCMT1176 | Streptococcus pneumoniae |
| TCMT1178 | Actinomyces viscosus |
| TCMT1179 | Escherichia coli ATCC 8739 |
| TCMT1181 | Mycobacterium tuberculosis H37Ra |
| TCMT1186 | Plasmodium yoelii yoelii |
| TCMT1189 | Pseudomonas fluorescens |
| TCMT1209 | Staphylococcus haemolyticus |
| TCMT1210 | Streptococcus sobrinus |
| TCMT1211 | Fusobacterium nucleatum |
| TCMT1212 | Verticillium dahliae |
| TCMT1213 | Neisseria gonorrhoeae |
| TCMT1214 | Enterococcus faecium |
| TCMT1215 | Pseudomonas aeruginosa PAO1 |
| TCMT1218 | Staphylococcus aureus |
| TCMT1223 | Staphylococcus epidermidis |
| TCMT1224 | Proteus mirabilis |
| TCMT1226 | Klebsiella pneumoniae |
| TCMT1227 | Streptococcus |
| TCMT1229 | Enterococcus faecalis |
| TCMT1232 | Pseudomonas aeruginosa |
| TCMT1234 | Bacillus coagulans |
| TCMT1235 | Clostridium sporogenes |
| TCMT1236 | Mycobacterium bovis |
| TCMT1237 | Mycobacterium kansasii |
| TCMT1238 | Mycobacterium xenopi |
| TCMT1239 | Mycobacterium marinum |
| TCMT1243 | Aspergillus flavus |
| TCMT1246 | Escherichia coli |
| TCMT1248 | Hepatitis C virus |
| TCMT1249 | Dengue virus 2 |
| TCMT1251 | Candida albicans |
| TCMT1253 | Penicillium chrysogenum |
| TCMT1255 | Human immunodeficiency virus 1 |
| TCMT1284 | Penicillium expansum |
| TCMT1286 | Bacillus cereus |
| TCMT1294 | Human parainfluenza virus 3 |
| TCMT1321 | Staphylococcus hominis |
| TCMT1343 | Staphylococcus simulans |
| TCMT1344 | Staphylococcus sciuri |
| TCMT1346 | Helicobacter pylori |
| TCMT1349 | Helicobacter pylori SS1 |
| TCMT1361 | Neisseria meningitidis |
| TCMT1370 | Prevotella melaninogenica |
| TCMT1382 | Plasmodium falciparum (isolate K1 / Thailand) |
| TCMT1393 | Vibrio sp. |
| TCMT1412 | Salmonella typhimurium |
| TCMT1438 | Plasmodium falciparum |
| TCMT1439 | Mycobacterium smegmatis |
| TCMT1442 | Leishmania donovani |
| TCMT1443 | Leishmania amazonensis |
| TCMT1447 | Respiratory syncytial virus |
| TCMT1448 | Enterobacter aerogenes |
| TCMT1449 | Influenza A virus |
| TCMT1450 | Plasmodium falciparum 3D7 |
| TCMT1454 | Bacillus subtilis |
| TCMT1455 | Mycobacterium tuberculosis H37Rv |
| TCMT1457 | Leishmania major |
| TCMT1458 | Filobasidiella neoformans |
| TCMT1462 | Streptococcus mutans |
| TCMT1463 | Mycobacterium tuberculosis |
| TCMT1464 | Hepatitis B virus |
| TCMT1465 | Entamoeba histolytica |
| GO Term | GO Name | Enriched Genes | Log10 Adjusted P-value |
|---|---|---|---|
| [BP] GO:0008202 | steroid metabolic process | AKR1B1, AKR1B10, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, FDPS, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 10.0434 |
| [BP] GO:0006629 | lipid metabolic process | ACHE, ADORA1, AKR1B1, AKR1B10, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, FABP3, FABP4, FDPS, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, PPARA | 8.32481 |
| [BP] GO:0015701 | bicarbonate transport | CA1, CA12, CA14, CA2, CA4, CA7, CA9 | 7.5221 |
| [BP] GO:0042445 | hormone metabolic process | ACHE, AKR1B1, CYP19A1, CYP1A1, CYP1B1, ESR1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 7.37812 |
| [BP] GO:0019748 | secondary metabolic process | AKR1B1, AKR1B10, BCL2, CYP1A1, CYP1A2, CYP1B1, TYR | 7.15645 |
| [BP] GO:0008152 | metabolic process | ACHE, ADORA1, AKR1B1, AKR1B10, ALPL, AOX1, BCL2, CA1, CA12, CA2, CA4, CA7, CA9, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, FABP3, FABP4, FDPS, FLT3, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, MMP12, POLA1, POLB, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 7.13444 |
| [BP] GO:0033993 | response to lipid | ALPL, BCL2, CA2, CA9, CDK6, CSNK2A1, CYP1A1, CYP1A2, ESR1, ESRRA, FABP3, FLT3, HSD11B2, HSD17B2, TYR | 6.97387 |
| [BP] GO:0006730 | one-carbon metabolic process | CA1, CA12, CA2, CA4, CA7, CA9 | 6.39584 |
| [BP] GO:0044281 | small molecule metabolic process | AKR1B1, AKR1B10, AOX1, CA1, CA12, CA2, CA4, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, FABP3, FDPS, FUT7, GBA2, PPARA, TYR, XDH | 6.1028 |
| [BP] GO:0065008 | regulation of biological quality | ACHE, ADORA1, AKR1B1, BCL2, CA12, CA2, CA7, CDK6, CYP19A1, CYP1A1, CYP1B1, ESR1, F3, FABP3, FABP4, FLT3, HSD11B1, HSD11B2, HSD17B1, HSD17B2, POLA1, POLB, PPARA, TNKS, TNKS2, XDH | 5.53669 |
| [BP] GO:1901700 | response to oxygen-containing compound | AKR1B1, ALPL, BCL2, CA9, CDK6, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, FABP3, HSD11B2, HSD17B2, POLB, PPARA, TYR | 5.53669 |
| [BP] GO:0009725 | response to hormone | AKR1B1, ALPL, BCL2, CA2, CA9, CSNK2A1, CYP1A2, ESR1, ESRRA, FABP3, FLT3, HSD11B2, PPARA | 5.49818 |
| [BP] GO:0034754 | cellular hormone metabolic process | AKR1B1, CYP19A1, CYP1A1, CYP1B1, ESR1, HSD17B1, HSD17B2 | 5.2008 |
| [BP] GO:0042446 | hormone biosynthetic process | AKR1B1, CYP19A1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 5.2008 |
| [BP] GO:0048513 | animal organ development | ACHE, BCL2, CA2, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, ESR1, ESRRA, ESRRB, FLT3, HSD11B1, HSD17B2, POLB, PPARA, TYR | 5.2008 |
| [BP] GO:0010033 | response to organic substance | AKR1B1, ALPL, BCL2, CA2, CA9, CDK6, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, FABP3, FABP4, FLT3, HSD11B2, HSD17B2, POLB, PPARA, TYR | 5.18618 |
| [BP] GO:0014070 | response to organic cyclic compound | ALPL, BCL2, CA2, CA9, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, FLT3, HSD11B2, TYR | 5.1142 |
| [BP] GO:0006694 | steroid biosynthetic process | AKR1B1, CYP19A1, FDPS, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 4.85941 |
| [BP] GO:0010817 | regulation of hormone levels | ACHE, ADORA1, AKR1B1, CYP19A1, CYP1A1, CYP1B1, ESR1, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 4.79415 |
| [BP] GO:0032847 | regulation of cellular pH reduction | BCL2, CA2, CA7 | 4.46412 |
| [BP] GO:0044237 | cellular metabolic process | ACHE, AKR1B1, AKR1B10, ALPL, AOX1, BCL2, CA1, CA12, CA2, CA4, CA7, CA9, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, FABP3, FABP4, FDPS, FLT3, FUT7, GBA2, HSD17B1, HSD17B2, POLA1, POLB, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 4.19697 |
| [BP] GO:0055114 | oxidation-reduction process | AKR1B1, AKR1B10, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, HSD11B1, HSD11B2, HSD17B1, HSD17B2, TYR, XDH | 4.19697 |
| [BP] GO:0016042 | lipid catabolic process | ADORA1, AKR1B10, CYP19A1, CYP1A2, CYP1B1, FABP3, FABP4, GBA2 | 3.90641 |
| [BP] GO:0042221 | response to chemical | AKR1B1, ALPL, BCL2, CA2, CA9, CDK6, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, FABP3, FABP4, FLT3, HSD11B2, HSD17B2, POLB, PPARA, TYR | 3.82871 |
| [BP] GO:0008210 | estrogen metabolic process | CYP19A1, CYP1B1, HSD17B1, HSD17B2 | 3.82468 |
| [BP] GO:0009719 | response to endogenous stimulus | AKR1B1, ALPL, BCL2, CA2, CA9, CSNK2A1, CYP1A2, ESR1, ESRRA, FABP3, FLT3, HSD11B2, PPARA | 3.80172 |
| [BP] GO:0044238 | primary metabolic process | ACHE, ADORA1, AKR1B1, AKR1B10, ALPL, AOX1, BCL2, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, FABP3, FABP4, FDPS, FLT3, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, MMP12, POLA1, POLB, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 3.7484 |
| [BP] GO:1901615 | organic hydroxy compound metabolic process | AKR1B1, AKR1B10, BCL2, CYP19A1, CYP1A1, CYP1B1, FDPS, GBA2, TYR | 3.66409 |
| [BP] GO:0015711 | organic anion transport | CA1, CA12, CA14, CA2, CA4, CA7, CA9, FABP3, PPARA | 3.63813 |
| [BP] GO:0008610 | lipid biosynthetic process | ACHE, AKR1B1, CSNK2A1, CYP19A1, CYP1A1, FDPS, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.62085 |
| [BP] GO:0048856 | anatomical structure development | ACHE, ADORA1, AKR1B1, ALPL, BCL2, CA2, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, ESRRB, FLT3, GBA2, HSD11B1, HSD17B2, POLB, PPARA, TYR | 3.41568 |
| [BP] GO:0032502 | developmental process | ACHE, ADORA1, AKR1B1, ALPL, BCL2, CA2, CA9, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, ESRRB, FABP4, FLT3, FUT7, GBA2, HSD11B1, HSD17B2, POLB, PPARA, TNKS2, TYR | 3.36959 |
| [BP] GO:0097267 | omega-hydroxylase P450 pathway | CYP1A1, CYP1A2, CYP1B1 | 3.2186 |
| [BP] GO:0044255 | cellular lipid metabolic process | ACHE, AKR1B10, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, FABP3, FABP4, FDPS, FUT7, GBA2, PPARA | 3.14672 |
| [BP] GO:0071704 | organic substance metabolic process | ACHE, ADORA1, AKR1B1, AKR1B10, ALPL, AOX1, BCL2, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, FABP3, FABP4, FDPS, FLT3, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, MMP12, POLA1, POLB, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 3.14672 |
| [BP] GO:0042127 | regulation of cell proliferation | ADORA1, ADORA3, AKR1B1, BCL2, CDC25B, CDK6, CSNK2A1, CYP1B1, ESR1, ESRRA, F3, FABP3, FLT3, MMP12, XDH | 2.93076 |
| [BP] GO:0010647 | positive regulation of cell communication | ADORA1, AKR1B1, BCL2, CA2, CA7, CSNK2A1, CYP19A1, CYP1B1, F3, FLT3, MMP12, PTPN1, TNKS, TNKS2, XDH | 2.91635 |
| [BP] GO:0006703 | estrogen biosynthetic process | CYP19A1, HSD17B1, HSD17B2 | 2.91635 |
| [BP] GO:0023056 | positive regulation of signaling | ADORA1, AKR1B1, BCL2, CA2, CA7, CSNK2A1, CYP19A1, CYP1B1, F3, FLT3, MMP12, PTPN1, TNKS, TNKS2, XDH | 2.9034 |
| [BP] GO:0006820 | anion transport | CA1, CA12, CA14, CA2, CA4, CA7, CA9, FABP3, PPARA | 2.82469 |
| [BP] GO:0006721 | terpenoid metabolic process | AKR1B10, CYP1A1, CYP1A2, CYP1B1, FDPS | 2.76914 |
| [BP] GO:0009115 | None | AOX1, XDH | 2.76914 |
| [BP] GO:0016137 | None | AKR1B1, AKR1B10, GBA2 | 2.52282 |
| [BP] GO:0006720 | isoprenoid metabolic process | AKR1B10, CYP1A1, CYP1A2, CYP1B1, FDPS | 2.46654 |
| [BP] GO:0009056 | catabolic process | ACHE, ADORA1, AKR1B10, AOX1, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, FABP3, FABP4, FUT7, GBA2, MMP12, XDH | 2.41791 |
| [BP] GO:0043401 | steroid hormone mediated signaling pathway | ESR1, ESR2, ESRRA, ESRRB, PPARA | 2.39543 |
| [BP] GO:0050896 | response to stimulus | ACHE, ADORA1, ADORA3, AKR1B1, ALPL, BCL2, CA2, CA9, CDK6, CSNK2A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESRRA, F3, FABP3, FABP4, FLT3, HSD11B2, HSD17B2, MMP12, POLA1, POLB, PPARA, PTPN1, TYR | 2.34451 |
| [BP] GO:0019373 | epoxygenase P450 pathway | CYP1A1, CYP1A2, CYP1B1 | 2.34451 |
| [BP] GO:0046110 | None | AOX1, XDH | 2.34451 |
| [BP] GO:0032849 | positive regulation of cellular pH reduction | CA2, CA7 | 2.34451 |
| [BP] GO:0009404 | toxin metabolic process | CYP1A1, CYP1A2, CYP1B1 | 2.23508 |
| [BP] GO:1901360 | None | ACHE, AKR1B1, AKR1B10, AOX1, BCL2, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, FDPS, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, POLA1, POLB, PPARA, TYR, XDH | 2.2121 |
| [BP] GO:1903409 | reactive oxygen species biosynthetic process | CYP1A1, CYP1A2, CYP1B1 | 2.1884 |
| [BP] GO:0070213 | None | TNKS, TNKS2 | 2.08553 |
| [BP] GO:0006145 | None | AOX1, XDH | 2.08553 |
| [BP] GO:0018894 | dibenzo-p-dioxin metabolic process | CYP1A1, CYP1A2 | 2.08553 |
| [BP] GO:0006367 | transcription initiation from RNA polymerase II promoter | ESR1, ESR2, ESRRA, ESRRB, PPARA | 2.02977 |
| [BP] GO:0022900 | electron transport chain | AKR1B1, AOX1, CYP19A1, CYP1A2, XDH | 2.00884 |
| [CC] GO:0044432 | endoplasmic reticulum part | BCL2, CYP19A1, CYP1A1, CYP1A2, CYP1B1, FLT3, GBA2, HSD11B1, HSD11B2, HSD17B2, PTPN1 | 1.49857 |
| [CC] GO:0043227 | membrane-bounded organelle | ACHE, ADORA1, AKR1B1, AKR1B10, ALPL, AOX1, BCL2, CA1, CA2, CA4, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, FABP3, FABP4, FDPS, FLT3, FUT7, GBA2, MMP12, POLA1, POLB, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 1.49136 |
| [CC] GO:0044444 | cytoplasmic part | ACHE, ADORA1, AKR1B1, AKR1B10, AOX1, BCL2, CA1, CA2, CA4, CA7, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, FABP3, FABP4, FDPS, FLT3, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, POLA1, PTPN1, TNKS, TNKS2, TYR, XDH | 1.49136 |
| [CC] GO:0005789 | endoplasmic reticulum membrane | BCL2, CYP19A1, CYP1A1, CYP1A2, CYP1B1, GBA2, HSD11B1, HSD11B2, HSD17B2 | 1.3474 |
| [CC] GO:0043231 | intracellular membrane-bounded organelle | ACHE, ADORA1, AKR1B1, AKR1B10, BCL2, CA4, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, FABP4, FDPS, FLT3, FUT7, GBA2, MMP12, POLA1, POLB, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 1.01554 |
| [MF] GO:0004089 | carbonate dehydratase activity | CA1, CA12, CA14, CA2, CA4, CA7, CA9 | 10.4296 |
| [MF] GO:0046914 | transition metal ion binding | AOX1, CA1, CA12, CA2, CA4, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, MMP12, PPARA, PTPN1, TNKS, TYR, XDH | 10.1598 |
| [MF] GO:0003824 | catalytic activity | ACHE, ADORA1, AKR1B1, AKR1B10, ALPL, AOX1, CA1, CA12, CA14, CA2, CA4, CA7, CA9, CDC25B, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, F3, FDPS, FLT3, FUT7, GBA2, HSD11B1, HSD11B2, HSD17B1, HSD17B2, MMP12, POLA1, POLB, PTPN1, TNKS, TNKS2, TYR, XDH | 7.71035 |
| [MF] GO:0016835 | carbon-oxygen lyase activity | CA1, CA12, CA14, CA2, CA4, CA7, CA9, POLB | 7.5287 |
| [MF] GO:0016836 | hydro-lyase activity | CA1, CA12, CA14, CA2, CA4, CA7, CA9 | 7.00295 |
| [MF] GO:0043167 | ion binding | ACHE, ALPL, AOX1, CA1, CA12, CA14, CA2, CA4, CA7, CA9, CDK6, CSNK2A1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, F3, FABP3, FABP4, FDPS, FLT3, HSD17B1, MMP12, POLA1, POLB, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 5.91727 |
| [MF] GO:0016614 | oxidoreductase activity, acting on CH-OH group of donors | AKR1B1, AKR1B10, AOX1, HSD11B1, HSD11B2, HSD17B1, HSD17B2, XDH | 5.85662 |
| [MF] GO:0008270 | zinc ion binding | CA1, CA12, CA2, CA4, CA7, CA9, ESR1, ESR2, ESRRA, ESRRB, MMP12, PPARA, PTPN1, TNKS | 5.43786 |
| [MF] GO:0016491 | oxidoreductase activity | AKR1B1, AKR1B10, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, HSD11B1, HSD11B2, HSD17B1, HSD17B2, TYR, XDH | 5.10992 |
| [MF] GO:0016829 | lyase activity | CA1, CA12, CA14, CA2, CA4, CA7, CA9, POLB | 5.04617 |
| [MF] GO:0043169 | cation binding | ACHE, ALPL, AOX1, CA1, CA12, CA14, CA2, CA4, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, FDPS, MMP12, POLA1, POLB, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 5.03685 |
| [MF] GO:0046872 | metal ion binding | ALPL, AOX1, CA1, CA12, CA14, CA2, CA4, CA7, CA9, CYP19A1, CYP1A1, CYP1A2, CYP1B1, ESR1, ESR2, ESRRA, ESRRB, FDPS, MMP12, POLA1, POLB, PPARA, PTPN1, TNKS, TNKS2, TYR, XDH | 4.56235 |
| [MF] GO:0005496 | steroid binding | ESR1, ESR2, ESRRA, ESRRB, HSD11B2, HSD17B1 | 4.45632 |
| [MF] GO:0098531 | transcription factor activity, direct ligand regulated sequence-specific DNA binding | ESR1, ESR2, ESRRA, ESRRB, PPARA | 4.19697 |
| [MF] GO:0004879 | nuclear receptor activity | ESR1, ESR2, ESRRA, ESRRB, PPARA | 4.19697 |
| [MF] GO:0070330 | aromatase activity | CYP19A1, CYP1A1, CYP1A2, CYP1B1 | 3.87093 |
| [MF] GO:0003707 | steroid hormone receptor activity | ESR1, ESR2, ESRRA, ESRRB, PPARA | 3.82871 |
| [MF] GO:0016616 | oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | AKR1B1, AKR1B10, HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.7484 |
| [MF] GO:0016712 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | CYP19A1, CYP1A1, CYP1A2, CYP1B1 | 3.71743 |
| [MF] GO:0033764 | steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.66409 |
| [MF] GO:0016229 | steroid dehydrogenase activity | HSD11B1, HSD11B2, HSD17B1, HSD17B2 | 3.56347 |
| [MF] GO:0048037 | cofactor binding | AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, HSD11B2, HSD17B1, POLA1, XDH | 3.1676 |
| [MF] GO:0005506 | iron ion binding | AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, XDH | 3.10444 |
| [MF] GO:0004497 | monooxygenase activity | CYP19A1, CYP1A1, CYP1A2, CYP1B1, TYR | 2.95233 |
| [MF] GO:0008289 | lipid binding | ESR1, ESR2, ESRRA, ESRRB, F3, FABP3, FABP4, HSD11B2, HSD17B1, PPARA | 2.91635 |
| [MF] GO:0016903 | None | AKR1B1, AKR1B10, AOX1, XDH | 2.91635 |
| [MF] GO:0019825 | oxygen binding | CYP19A1, CYP1A1, CYP1A2, CYP1B1 | 2.89004 |
| [MF] GO:0038052 | RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | ESR1, ESR2 | 2.76914 |
| [MF] GO:0003845 | None | HSD11B1, HSD11B2 | 2.76914 |
| [MF] GO:0009055 | electron transfer activity | AKR1B1, AOX1, CYP19A1, CYP1A2, XDH | 2.76463 |
| [MF] GO:0016705 | oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen | CYP19A1, CYP1A1, CYP1A2, CYP1B1, TYR | 2.08553 |
| [MF] GO:0034056 | estrogen response element binding | ESR1, ESR2 | 2.08553 |
| KEGG Pathway ID | Enriched Genes | Log10 Adjusted P-value |
|---|---|---|
| Nitrogen metabolism_Homo sapiens_hsa00910 | CA12, CA1, CA2, CA4, CA7, CA9, CA14 | 12.3773 |
| Steroid hormone biosynthesis_Homo sapiens_hsa00140 | HSD11B1, HSD11B2, HSD17B1, HSD17B2, CYP1A2, CYP1A1, CYP1B1, CYP19A1 | 10.4238 |
| Metabolic pathways_Homo sapiens_hsa01100 | FDPS, AKR1B1, TYR, GBA2, CYP19A1, HSD11B1, POLA1, FUT7, AKR1B10, HSD17B1, HSD17B2, CYP1A2, CYP1A1, AOX1, ALPL, XDH | 6.6017 |
| Ovarian steroidogenesis_Homo sapiens_hsa04913 | HSD17B1, HSD17B2, CYP1A1, CYP1B1, CYP19A1 | 5.5812 |
| Tryptophan metabolism_Homo sapiens_hsa00380 | CYP1A2, CYP1A1, AOX1, CYP1B1 | 4.3584 |
| Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | HSD11B1, CYP1A2, CYP1A1, CYP1B1 | 3.3857 |
| Chemical carcinogenesis_Homo sapiens_hsa05204 | HSD11B1, CYP1A2, CYP1A1, CYP1B1 | 3.2533 |
| Retinol metabolism_Homo sapiens_hsa00830 | CYP1A2, CYP1A1, AOX1 | 2.2839 |
| PPAR signaling pathway_Homo sapiens_hsa03320 | FABP3, FABP4, PPARA | 2.2534 |
| Sphingolipid signaling pathway_Homo sapiens_hsa04071 | ADORA3, BCL2, ADORA1 | 1.706 |
| MicroRNAs in cancer_Homo sapiens_hsa05206 | CDK6, BCL2, CYP1B1, CDC25B | 1.5355 |
| Tyrosine metabolism_Homo sapiens_hsa00350 | AOX1, TYR | 1.6955 |
| Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | FABP4, ADORA1 | 1.3711 |
| Galactose metabolism_Homo sapiens_hsa00052 | AKR1B10, AKR1B1 | 1.7275 |
| Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | CA2, CA4 | 1.9208 |
| Glycerolipid metabolism_Homo sapiens_hsa00561 | AKR1B10, AKR1B1 | 1.3508 |
| Prolactin signaling pathway_Homo sapiens_hsa04917 | ESR1, ESR2 | 1.2281 |
| Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | AKR1B10, AKR1B1 | 1.6955 |
| Fructose and mannose metabolism_Homo sapiens_hsa00051 | AKR1B10, AKR1B1 | 1.7066 |
| Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | CYP1A2, AOX1 | 1.2422 |
| Adherens junction_Homo sapiens_hsa04520 | PTPN1, CSNK2A1 | 1.2256 |
| AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | BCL2, F3 | 1.0598 |
| Small cell lung cancer_Homo sapiens_hsa05222 | CDK6, BCL2 | 1.1396 |
| Estrogen signaling pathway_Homo sapiens_hsa04915 | ESR1, ESR2 | 1.0598 |
| Cholinergic synapse_Homo sapiens_hsa04725 | ACHE, BCL2 | 1.0147 |
| NF-kappa B signaling pathway_Homo sapiens_hsa04064 | CSNK2A1, BCL2 | 1.0933 |
| Insulin resistance_Homo sapiens_hsa04931 | PTPN1, PPARA | 1.0147 |
| Measles_Homo sapiens_hsa05162 | CDK6, CSNK2A1 | 0.8959 |
| Hepatitis B_Homo sapiens_hsa05161 | CDK6, BCL2 | 0.8668 |
| Cell cycle_Homo sapiens_hsa04110 | CDK6, CDC25B | 0.9551 |
| Jak-STAT signaling pathway_Homo sapiens_hsa04630 | BCL2, AOX1 | 0.83 |
| cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | ADORA3, ADORA1 | 0.806 |
| Pathways in cancer_Homo sapiens_hsa05200 | CDK6, FLT3, BCL2 | 0.806 |
| Purine metabolism_Homo sapiens_hsa00230 | POLA1, XDH | 0.806 |
| Epstein-Barr virus infection_Homo sapiens_hsa05169 | CSNK2A1, BCL2 | 0.7662 |
| cAMP signaling pathway_Homo sapiens_hsa04024 | ADORA1, PPARA | 0.7662 |
| Viral carcinogenesis_Homo sapiens_hsa05203 | POLB, CDK6 | 0.7662 |
| HTLV-I infection_Homo sapiens_hsa05166 | POLB, FDPS | 0.6568 |
| Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | ADORA3, ADORA1 | 0.6364 |
| PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | CDK6, BCL2 | 0.595 |
| Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | CDC25B | 0.5797 |
| Apoptosis_Homo sapiens_hsa04210 | BCL2 | 0.5047 |
| Prostate cancer_Homo sapiens_hsa05215 | BCL2 | 0.595 |
| Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | FLT3 | 0.3382 |
| Glioma_Homo sapiens_hsa05214 | CDK6 | 0.6364 |
| MAPK signaling pathway_Homo sapiens_hsa04010 | CDC25B | 0.3463 |
| Insulin signaling pathway_Homo sapiens_hsa04910 | PTPN1 | 0.5047 |
| Melanogenesis_Homo sapiens_hsa04916 | TYR | 0.5787 |
| Protein processing in endoplasmic reticulum_Homo sapiens_hsa04141 | BCL2 | 0.4554 |
| Hepatitis C_Homo sapiens_hsa05160 | PPARA | 0.505 |
| Hematopoietic cell lineage_Homo sapiens_hsa04640 | FLT3 | 0.595 |
| Chronic myeloid leukemia_Homo sapiens_hsa05220 | CDK6 | 0.6323 |
| Tight junction_Homo sapiens_hsa04530 | CSNK2A1 | 0.5047 |
| Pancreatic cancer_Homo sapiens_hsa05212 | CDK6 | 0.6364 |
| Central carbon metabolism in cancer_Homo sapiens_hsa05230 | FLT3 | 0.6364 |
| Glucagon signaling pathway_Homo sapiens_hsa04922 | PPARA | 0.5787 |
| Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | ESRRB | 0.5047 |
| Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | ESR1 | 0.5399 |
| HIF-1 signaling pathway_Homo sapiens_hsa04066 | BCL2 | 0.5764 |
| Colorectal cancer_Homo sapiens_hsa05210 | BCL2 | 0.6364 |
| Neurotrophin signaling pathway_Homo sapiens_hsa04722 | BCL2 | 0.5385 |
| Influenza A_Homo sapiens_hsa05164 | FDPS | 0.4475 |
| Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | PPARA | 0.4915 |
| Morphine addiction_Homo sapiens_hsa05032 | ADORA1 | 0.5919 |
| Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | BCL2 | 0.4942 |
| Wnt signaling pathway_Homo sapiens_hsa04310 | CSNK2A1 | 0.5047 |
| Focal adhesion_Homo sapiens_hsa04510 | BCL2 | 0.4177 |
| Proteoglycans in cancer_Homo sapiens_hsa05205 | ESR1 | 0.4177 |
| Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | FLT3 | 0.4465 |
| Tuberculosis_Homo sapiens_hsa05152 | BCL2 | 0.4465 |
| Melanoma_Homo sapiens_hsa05218 | CDK6 | 0.6364 |
| Herpes simplex infection_Homo sapiens_hsa05168 | CSNK2A1 | 0.4412 |
| Non-small cell lung cancer_Homo sapiens_hsa05223 | CDK6 | 0.656 |
| Toxoplasmosis_Homo sapiens_hsa05145 | BCL2 | 0.5399 |
| Glycerophospholipid metabolism_Homo sapiens_hsa00564 | ACHE | 0.5824 |
| Ribosome biogenesis in eukaryotes_Homo sapiens_hsa03008 | CSNK2A1 | 0.595 |
| Acute myeloid leukemia_Homo sapiens_hsa05221 | FLT3 | 0.656 |
| Gastric acid secretion_Homo sapiens_hsa04971 | CA2 | 0.6323 |
| Renin secretion_Homo sapiens_hsa04924 | ADORA1 | 0.6364 |
| Pancreatic secretion_Homo sapiens_hsa04972 | CA2 | 0.5824 |
| Adipocytokine signaling pathway_Homo sapiens_hsa04920 | PPARA | 0.6364 |
| Pyrimidine metabolism_Homo sapiens_hsa00240 | POLA1 | 0.5743 |
| Peroxisome_Homo sapiens_hsa04146 | XDH | 0.5989 |
| Complement and coagulation cascades_Homo sapiens_hsa04610 | F3 | 0.6124 |
| p53 signaling pathway_Homo sapiens_hsa04115 | CDK6 | 0.6364 |
| Bile secretion_Homo sapiens_hsa04976 | CA2 | 0.6364 |
| Endocrine and other factor-regulated calcium reabsorption_Homo sapiens_hsa04961 | ESR1 | 0.6957 |
| Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | BCL2 | 0.6782 |
| Valine, leucine and isoleucine degradation_Homo sapiens_hsa00280 | AOX1 | 0.6953 |
| Drug metabolism - other enzymes_Homo sapiens_hsa00983 | XDH | 0.6957 |
| Sphingolipid metabolism_Homo sapiens_hsa00600 | GBA2 | 0.6957 |
| Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | HSD11B2 | 0.7476 |
| Caffeine metabolism_Homo sapiens_hsa00232 | CYP1A2, XDH | 3.1741 |
| Linoleic acid metabolism_Homo sapiens_hsa00591 | CYP1A2 | 0.806 |
| DNA replication_Homo sapiens_hsa03030 | POLA1 | 0.7662 |
| Other types of O-glycan biosynthesis_Homo sapiens_hsa00514 | FUT7 | 0.7878 |
| Base excision repair_Homo sapiens_hsa03410 | POLB | 0.7716 |
| Glycosphingolipid biosynthesis - lacto and neolacto series_Homo sapiens_hsa00601 | FUT7 | 0.806 |
| Nicotinate and nicotinamide metabolism_Homo sapiens_hsa00760 | AOX1 | 0.806 |
| Collecting duct acid secretion_Homo sapiens_hsa04966 | CA2 | 0.806 |
| Terpenoid backbone biosynthesis_Homo sapiens_hsa00900 | FDPS | 0.833 |
| Other glycan degradation_Homo sapiens_hsa00511 | GBA2 | 0.8928 |
| Folate biosynthesis_Homo sapiens_hsa00790 | ALPL | 0.9586 |
| Vitamin B6 metabolism_Homo sapiens_hsa00750 | AOX1 | 1.2073 |